查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015121

眼科黏彈性手術器材市場：2026-2032年全球市場預測（依產品類型、成分、應用、最終用戶及通路分類）

Ophthalmic Viscosurgical Devices Market by Product Type, Composition, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，眼科黏彈性手術器械市場價值將達到 26.6 億美元，到 2026 年將成長至 28.1 億美元，到 2032 年將達到 41.8 億美元，複合年成長率為 6.68%。

主要市場統計數據
基準年 2025 26.6億美元
預計年份：2026年 28.1億美元
預測年份 2032 41.8億美元
複合年成長率 (%) 6.68%

眼科黏彈性手術器械的全面概述：闡述臨床意義、不斷變化的手術實踐挑戰以及關鍵的採購考慮因素。

本執行摘要重點概述了眼科黏彈性手術器械（OVD）及其在現代眼前節和後節手術中的關鍵作用。內容旨在幫助臨床負責人、採購負責人全面了解影響手術中心和醫院系統決策的臨床因素、產品創新、監管趨勢和不斷變化的流通結構。

從臨床、技術、監管和商業性等多個角度綜合觀點推動眼科黏彈性手術器材整個價值鏈快速轉型的因素。

近年來，臨床、技術和商業性因素的共同作用，促成了多項變革性變化，重塑了光學視覺釋放劑（OVD）的市場格局。臨床上，微切口白內障手術和高階人工水晶體的日益普及，增加了對能夠最佳化人工水晶體定位、最大限度減少殘留並維持前房穩定性的OVD的需求。同時，在外科手術實踐中，越來越多的手術轉向門診進行，這增加了對易於操作且即使在高週轉率條件下也能保持性能穩定的產品的需求。這些臨床進展與產品創新密切相關，配方成分的進步催生了黏彈性自適應和複合成分產品，這些產品在抽吸過程中更易於清除，同時兼具維持眼內空間和保護內皮細胞的雙重優勢。

對 2025 年美國關稅措施將如何造成供應鏈重組、採購模式變化以及對本地生產投資的獎勵進行嚴格評估。

2025年美國實施的關稅措施的累積影響將為製造商、經銷商和醫療保健提供者帶來一系列新的營運和策略考量。關稅帶來的成本壓力將波及整個供應鏈，可能增加進口原料和成品口腔黏膜下注射（OVD）產品的成本。按固定還款計畫運作且採購預算有限的機構可能面臨額外負擔，這可能導致與供應商的談判更加嚴格，更加重視總體擁有成本，並在可行的情況下轉向國內生產替代方案。企業的因應措施不會千篇一律。擁有本地生產能力的大規模綜合製造商可以透過規模經濟吸收或減輕部分關稅影響，而依賴跨境零件採購的小規模供應商則可能面臨更嚴峻的利潤率壓力。

將產品配方、成分科學、臨床應用、最終用戶需求和分銷管道經濟與策略重點連結起來的詳細細分分析。

要深入了解細分市場的性能和產品策略，最佳方法是從多個分析觀點出發，全面揭示其臨床適用性、商業性潛力和操作要求。基於產品類型的分析區分了內聚型、複雜型、可分散型和黏彈性適應型配方。內聚型產品通常優先考慮腔室維護和易於移除，可分散型產品強調在複雜手術過程中對內皮的保護和保留，複雜型配方則平衡了這些特性，而黏彈性適應型溶液則可根據不同的剪切條件調整其特性。基於成分的細分突出了複雜型配方、羥丙基甲基纖維素和透明質酸鈉在決定黏彈性行為、使用者偏好和對原料的依賴性方面的作用。由於其黏彈性穩定性，透明質酸鈉仍然是許多先進配方中的首選成分，而羥丙基甲基纖維素則提供了在特定手術流程中至關重要的操作性能。

以區域差異為重點的觀點，識別世界各地獨特的採購實務、法規要求和供應鏈考量。

區域趨勢影響產品偏好、監管應對措施和供應鏈設計，從而在關鍵區域形成不同的競爭格局。在美洲，穩定的手術量、成熟的採購體係以及眾多門診手術中心，催生了對各種OVD製劑的需求，這些製劑優先考慮操作一致性和合規性。在這些市場中運作的製造商必須平衡快速交付和嚴格品管的期望，並且通常優先考慮產生臨床證據和與關鍵意見領袖（KOL）合作，以促進產品市場滲透。

策略競爭分析重點闡述了創新、供應連續性和附加價值服務如何重新定義OVD產業的領導地位和差異化優勢。

口腔病毒分泌物（OVD）領域的競爭格局呈現出傳統製造商、專業製造商和新興企業採用差異化的打入市場策略。主要企業正加大對配方科學的投入，以拓展臨床效用，同時也致力於改進包裝和給藥系統，從而提高操作便利性並減少廢棄物。其策略重點包括加強與臨床機構的直接合作，確保高純度透明質酸原料的穩定供應，以及利用監管部門的核准，拓展關鍵治療應用領域的適應症。

一份切實可行的策略藍圖，建議投資於配方研發、供應來源多元化、經營模式調整以及監管合規準備，以維持成長。

產業領導企業應考慮採取多管齊下的策略，涵蓋臨床差異化、供應鏈韌性、商業性靈活性和監管前瞻性。首先，他們應優先投資於配方科學，旨在透過改善內皮保護、提高移除便利性或最佳化黏彈性行為，實現顯著的臨床優勢，從而打造外科醫生能夠輕鬆融入標準工作流程的強大產品差異化優勢。其次，他們應透過策略性合約和供應商多角化來加強原物料採購體系，從而減輕貿易中斷的影響，並提升自身在成本和前置作業時間上的議價能力。

透明嚴謹的研究途徑，結合專家訪談、監管審查、臨床文獻整合和迭代檢驗，確保獲得可操作的見解。

本摘要的研究採用了結構化一手訪談、有針對性的二手資料分析和系統性檢驗驗證相結合的方法，以確保研究結果的穩健性和相關性。一手資料是透過對眼科醫生、門診和醫院採購負責人、監管專家以及高級銷售主管的詳細訪談收集的，相關人員從各自的角度提供了關於臨床重點、採購決定因素和供應鏈挑戰的背景觀點。二手資料包括公開的監管文件、臨床文獻、醫療設備註冊數據和企業披露信息，這些信息被整合起來以檢驗臨床聲明、生產實踐和分銷模式。

一份簡明扼要、綜合全面的分析報告，重點關注臨床因素、供應彈性以及為應對眼科醫療設備不斷變化的趨勢而必須採取的客製化商業策略。

總之，眼科黏彈劑（OVD）領域具有持續的臨床意義、加速的創新以及適應新的手術流程和採購現實的商業性環境等特徵。臨床需求仍然是主要驅動力。能夠可靠保護眼組織、支援先進的眼內手術並能無縫整合到高通量環境中的製劑將吸引臨床醫生和採購相關人員的注意。同時，供應鏈的韌性和監管的靈活性正成為至關重要的營運重點，尤其是在貿易政策不斷變化和原料供應波動的情況下。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：眼科黏彈性手術器材市場：依產品類型分類

  • 凝聚力
  • 複雜類型
  • 去中心化
  • 黏彈性自適應型

第9章 眼科黏彈性手術器材市場：依組件分類

  • 組合
  • 羥丙基甲基纖維素
  • 透明質酸鈉

第10章：眼科黏彈性手術器械市場：依應用領域分類

  • 白內障手術
  • 角膜手術
  • 青光眼手術
  • 玻璃體視網膜手術

第11章：眼科黏彈性手術器械市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章：眼科黏彈性手術器械市場：依分銷管道分類

  • 直銷
  • 銷售代理

第13章：眼科黏彈性手術器材市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：眼科黏彈性手術器材市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：眼科黏彈性手術器械市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國眼科黏彈性手術器械市場

第17章：中國黏彈性眼科手術器材市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alcon Inc.
  • Altacor Limited
  • Amring Pharmaceuticals Inc.
  • Bausch+Lomb Incorporated
  • Beaver-Visitec International, Inc.
  • Bohus BioTech AB
  • Carl Zeiss Meditec AG
  • CIMA Technology, Inc.
  • HOYA Corporation
  • Johnson & Johnson Vision Care, Inc.
  • Precision Lens Co. Ltd.
  • Rayner Intraocular Lenses Limited
  • Rumex International Corporation
  • Santen Pharmaceutical Co., Ltd.
  • Shanghai Haohai Biological Technology Co., Ltd.
Product Code: MRR-036C5CF3B495

The Ophthalmic Viscosurgical Devices Market was valued at USD 2.66 billion in 2025 and is projected to grow to USD 2.81 billion in 2026, with a CAGR of 6.68%, reaching USD 4.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.66 billion
Estimated Year [2026] USD 2.81 billion
Forecast Year [2032] USD 4.18 billion
CAGR (%) 6.68%

A comprehensive orientation to ophthalmic viscosurgical devices outlining clinical importance, evolving surgical practice pressures, and procurement imperatives

This executive summary provides a focused orientation to ophthalmic viscosurgical devices (OVDs) and their pivotal role in contemporary anterior and posterior segment surgery. The content is designed to equip clinical leaders, procurement executives, and product strategists with a balanced synthesis of clinical drivers, product innovation, regulatory dynamics, and distribution shift factors that collectively shape decision-making across surgical centers and hospital systems.

OVDs serve as indispensable adjuncts during cataract, corneal, glaucoma, and vitreoretinal procedures, protecting ocular tissues while enabling visualization and access. As surgical techniques continue to evolve toward smaller incisions and faster throughput, the expectations placed on OVD performance, handling characteristics, and supply reliability have intensified. This introduction outlines the framing assumptions used across subsequent sections, emphasizing clinical utility, supplier behavior, regulatory influences, and end-user procurement priorities. It sets the stage for deeper insights into transformative trends, tariff impacts, segmentation nuances, regional differentiation, and strategic actions that industry stakeholders should consider.

An integrated view of the clinical, technological, regulatory, and commercial forces driving rapid transformation across the ophthalmic viscosurgical devices value chain

Several transformative shifts have reshaped the OVD landscape in recent years, driven by converging clinical, technological, and commercial forces. Clinically, the widespread adoption of microincision cataract surgery and premium intraocular lenses has increased demand for OVDs that provide sustained anterior chamber stability while minimizing residue and optimizing intraocular lens positioning. Concurrently, surgical practice has migrated more procedures to ambulatory settings, creating a premium on products that combine ease of handling with consistent performance under high-turnover conditions. These clinical evolutions are tightly coupled with product innovation, where formulary advances are producing viscoadaptive and combination compositions intended to deliver dual benefits of space maintenance and endothelial protection, while enabling simplified removal during aspiration.

On the regulatory and quality front, heightened scrutiny over sterility assurance, supply chain traceability, and device classification has prompted manufacturers to invest in enhanced quality systems and in some cases to redesign packaging and labeling to align with new regional requirements. The supply chain itself is undergoing consolidation; strategic partnerships and selective vertical integration are being used to stabilize raw material sourcing-particularly for high-purity sodium hyaluronate-and to improve manufacturing resilience. Digital channels and direct-to-provider distribution models continue to expand, altering traditional distributor relationships and enabling more granular data capture on usage patterns. Taken together, these shifts are accelerating portfolio rationalization, encouraging investments in differentiated formulations and delivery systems, and elevating the importance of cross-functional collaboration between clinical, regulatory, and commercial teams.

A rigorous assessment of how 2025 tariff measures in the United States create supply chain recalibration, procurement shifts, and incentives for localized manufacturing investments

The cumulative effects of tariff measures implemented in the United States during 2025 introduce a new set of operational and strategic considerations for manufacturers, distributors, and healthcare providers. Tariff-induced cost pressures are likely to be transmitted through the supply chain, increasing landed costs for imported raw materials and finished OVD products. Facilities operating under fixed reimbursement schedules and constrained procurement budgets may experience added strain, prompting more rigorous supplier negotiations, greater emphasis on total cost of ownership, and potential shifts toward domestically produced alternatives where feasible. The operational response is not uniform; larger integrated manufacturers with localized production capabilities can absorb or mitigate some tariff impacts through scale, while smaller suppliers that rely on cross-border component sourcing may face more acute margin compression.

Procurement strategies at hospitals and ambulatory centers tend to adjust via longer contract cycles, expanded use of framework agreements that lock in prices, or heightened reliance on group purchasing organizations that aggregate demand to secure more favorable terms. In parallel, distributors may reconfigure inventory strategies to hedge against tariff volatility and to preserve service levels, increasing safety stock or rebalancing geographic inventory pools. On the innovation side, tariff pressure creates an incentive to optimize formulations for cost-effective raw material use and to redesign packaging to reduce import duty classifications where legally permissible. Over the medium term, policy-driven trade barriers can accelerate regional manufacturing investments and supplier diversification as companies seek to protect margin and maintain supply reliability for high-volume surgical settings. In sum, tariffs act as a catalyst for supply chain reconfiguration, procurement optimization, and selective onshoring where economic and regulatory conditions justify capital investment.

In-depth segmentation analysis that connects product formulation, composition science, clinical application, end-user requirements, and distribution channel economics to strategic priorities

Segment-level performance and product strategy are best understood through multiple analytical lenses that together reveal clinical fit, commercial potential, and operational requirements. Analysis by product type differentiates Cohesive, Combined, Dispersive, and Viscoadaptive formulations, where cohesive products typically prioritize chamber maintenance and facile removal, dispersive variants emphasize endothelial protection and retention during complex maneuvers, combined formulations seek to balance those attributes, and viscoadaptive solutions adapt properties under changing shear conditions. Composition-based segmentation highlights the role of Combination products, Hydroxypropyl Methylcellulose, and Sodium Hyaluronate in determining viscoelastic behavior, user preference, and raw material dependencies; sodium hyaluronate continues to be favored in many advanced formulations for its viscoelastic stability, while hydroxypropyl methylcellulose offers handling profiles valued in specific surgical workflows.

Application-based distinctions across Cataract Surgery, Corneal Surgery, Glaucoma Surgery, and Vitreoretinal Surgery illuminate divergent clinical requirements. Cataract procedures demand OVDs that enable predictable capsular support and lens placement, corneal interventions prioritize endothelial protection, glaucoma surgeries emphasize space maintenance for angle-based maneuvers, and vitreoretinal operations often require specialized handling during posterior segment access. End-user segmentation covering Ambulatory Surgery Centers, Hospitals, and Specialty Clinics underscores procurement and usage differences; ambulatory centers value products that support throughput and ease of use, hospitals often require a broader formulary to accommodate complex cases, and specialty clinics may demand niche formulations aligned to subspecialty procedures. Distribution channel analysis across Direct Sales, Distributor Partners, and Ecommerce reveals contrasting go-to-market models: direct sales can deliver tailored clinical support and contracting, distributor partners facilitate broad geographic reach and inventory management, and ecommerce channels provide convenience and data transparency but require robust logistics and regulatory compliance mechanisms. Combined, these segmentation perspectives inform product development priorities, clinical education programs, and commercial channel investments that align with specific procedural and customer needs.

A regionally nuanced perspective identifying distinct procurement behaviors, regulatory imperatives, and supply chain considerations across global territories

Regional dynamics shape product preferences, regulatory pathways, and supply chain design, producing differentiated competitive landscapes across major territories. In the Americas, established surgical volumes, mature procurement systems, and a strong presence of ambulatory surgery centers create demand for a wide range of OVD formulations that emphasize handling consistency and regulatory compliance. Manufacturers operating in these markets must balance rapid service expectations with stringent quality oversight, and they often prioritize clinical evidence generation and KOL engagement to support product adoption.

Europe, Middle East & Africa present a heterogeneous environment where divergent reimbursement frameworks, variable regulatory harmonization, and regional supply chain complexities necessitate localized market approaches. In some countries within this region, centralized procurement or hospital group purchasing drives price sensitivity, while in others, clinical preference and specialist networks exert stronger influence on adoption. Manufacturers benefit from adaptable regulatory strategies and targeted clinical programs to navigate this diversity. Asia-Pacific displays a combination of high-volume demand centers, rapid surgical capacity expansion, and growing domestic manufacturing capabilities. The region includes fast-growing ambulatory networks alongside large tertiary hospitals, and stakeholders often prioritize cost-effective formulations paired with robust supply continuity. Across all regions, cross-border regulatory alignment, export controls, and raw material sourcing considerations play pivotal roles in shaping manufacturing footprints and distribution strategies.

Strategic competitive analysis highlighting how innovation, supply continuity, and value-added services are redefining leadership and differentiation in the OVD sector

Competitive dynamics within the OVD space are characterized by a mix of legacy manufacturers, specialists, and emerging players employing differentiated go-to-market strategies. Leading firms are investing in formulation science to extend clinical utility while also refining packaging and delivery systems to improve handling and reduce waste. Strategic priorities include expanding direct clinical engagement, securing raw material supply chains for high-purity hyaluronate sources, and leveraging regulatory approvals to support label expansions in key therapeutic applications.

Smaller and mid-sized companies often focus on niche indications, cost-competitive formulations, or geographically targeted distribution partnerships to consolidate presence. Across tiers, companies are increasingly pursuing collaborative models that combine clinical training programs with bundled procurement offers for ambulatory centers and hospital systems. Mergers and acquisitions remain an active strategic lever, used to acquire proprietary formulations, expand manufacturing capacity, or access complementary distribution networks. Service differentiation through clinical education, post-market surveillance, and value-based contracting is becoming more central to competitive positioning as buyers expect not only product performance but also predictable supply and demonstrable outcomes support. Intellectual property management and quality system maturity continue to be critical determinants of competitive advantage, particularly for companies seeking to expand into regulated markets with rigorous approval requirements.

Actionable strategic roadmap recommending formulation investment, supply diversification, commercial model adaptation, and regulatory preparedness to sustain growth

Industry leaders should consider a multi-pronged approach that addresses clinical differentiation, supply resilience, commercial agility, and regulatory foresight. First, prioritize investment in formulation science that targets clear clinical advantages-whether through improved endothelial protection, ease of removal, or optimized viscoelastic behavior-to create defensible product differentiation that surgeons can readily adopt within standard workflows. Next, strengthen raw material sourcing through strategic agreements and diversified supplier bases to reduce exposure to trade disruptions and to improve negotiating leverage on cost and lead times.

Commercial models should be adapted to evolving procurement landscapes by expanding direct engagement with ambulatory surgery centers and large hospital systems, while refining distributor relationships to ensure geographic coverage and inventory responsiveness. Digital enablement across ordering, inventory visibility, and post-market feedback can enhance customer experience and provide actionable usage data. Regulatory and quality systems must be continuously upgraded to address emerging regional requirements and to accelerate label expansions; proactive engagement with regulatory authorities and investment in robust clinical evidence will facilitate market access. Finally, develop contingency plans for tariff and trade policy volatility that combine flexible inventory strategies, regional production options, and cost engineering to protect margins without compromising clinical performance. These recommendations together form an actionable roadmap to drive adoption, protect supply, and sustain competitive momentum.

A transparent and rigorous research approach combining expert interviews, regulatory review, clinical literature synthesis, and iterative triangulation to ensure actionable findings

The research underpinning this summary relied on a blend of structured primary interviews, targeted secondary analysis, and methodical triangulation to ensure robustness and relevance. Primary inputs were gathered through in-depth interviews with ophthalmic surgeons, procurement officers from ambulatory and hospital settings, regulatory experts, and senior commercial executives, all of whom provided contextual perspectives on clinical priorities, purchasing drivers, and supply chain challenges. Secondary inputs included publicly available regulatory documents, clinical literature, device registries, and corporate disclosures, which were synthesized to validate clinical claims, manufacturing practices, and distribution models.

Data and insight triangulation was applied to reconcile discrepancies between stakeholder perspectives and published information, with iterative validation cycles used to refine interpretations. The methodology incorporated careful attention to regional regulatory frameworks and to procedural trends that influence formulation selection and usage patterns. Where assumptions were required, they were explicitly tested through follow-up interviews and scenario analysis to assess sensitivity to policy shifts, procurement changes, and clinical adoption barriers. The overall approach emphasizes transparency in source provenance, disciplined cross-validation, and the integration of clinical and commercial viewpoints to produce actionable intelligence for decision-makers.

A concise synthesis emphasizing clinical drivers, supply resilience, and coordinated commercial strategies necessary to navigate evolving ophthalmic device dynamics

In closing, the OVD segment is marked by enduring clinical relevance, accelerating innovation, and a commercial landscape that is adapting to new surgical workflows and procurement realities. Clinical needs remain the primary driver: formulations that reliably protect ocular tissues, support advanced intraocular procedures, and integrate smoothly into high-throughput settings will command attention from clinicians and purchasing stakeholders alike. At the same time, supply chain resilience and regulatory agility have emerged as essential operational priorities, particularly in the context of trade policy shifts and fluctuating raw material access.

Stakeholders who align product development with clear procedural benefits, who invest in demonstrable clinical evidence, and who pursue flexible commercial models will be best positioned to capture long-term value. The interplay between formulation innovation, regional regulatory differences, and distribution model evolution underscores the need for coordinated strategies that span R&D, manufacturing, and customer engagement. By focusing on clinical differentiation, supply continuity, and responsive commercial execution, industry participants can navigate near-term disruptions while building durable competitive advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ophthalmic Viscosurgical Devices Market, by Product Type

  • 8.1. Cohesive
  • 8.2. Combined
  • 8.3. Dispersive
  • 8.4. Viscoadaptive

9. Ophthalmic Viscosurgical Devices Market, by Composition

  • 9.1. Combination
  • 9.2. Hydroxypropyl Methylcellulose
  • 9.3. Sodium Hyaluronate

10. Ophthalmic Viscosurgical Devices Market, by Application

  • 10.1. Cataract Surgery
  • 10.2. Corneal Surgery
  • 10.3. Glaucoma Surgery
  • 10.4. Vitreoretinal Surgery

11. Ophthalmic Viscosurgical Devices Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Ophthalmic Viscosurgical Devices Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributor Partners

13. Ophthalmic Viscosurgical Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Ophthalmic Viscosurgical Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Ophthalmic Viscosurgical Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Ophthalmic Viscosurgical Devices Market

17. China Ophthalmic Viscosurgical Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alcon Inc.
  • 18.6. Altacor Limited
  • 18.7. Amring Pharmaceuticals Inc.
  • 18.8. Bausch + Lomb Incorporated
  • 18.9. Beaver-Visitec International, Inc.
  • 18.10. Bohus BioTech AB
  • 18.11. Carl Zeiss Meditec AG
  • 18.12. CIMA Technology, Inc.
  • 18.13. HOYA Corporation
  • 18.14. Johnson & Johnson Vision Care, Inc.
  • 18.15. Precision Lens Co. Ltd.
  • 18.16. Rayner Intraocular Lenses Limited
  • 18.17. Rumex International Corporation
  • 18.18. Santen Pharmaceutical Co., Ltd.
  • 18.19. Shanghai Haohai Biological Technology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COHESIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COHESIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COHESIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISPERSIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISPERSIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISPERSIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VISCOADAPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VISCOADAPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VISCOADAPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMBINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HYDROXYPROPYL METHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SODIUM HYALURONATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SODIUM HYALURONATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SODIUM HYALURONATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CATARACT SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CATARACT SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CATARACT SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CORNEAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CORNEAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY CORNEAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GLAUCOMA SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GLAUCOMA SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GLAUCOMA SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VITREORETINAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VITREORETINAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY VITREORETINAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTOR PARTNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTOR PARTNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTOR PARTNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GCC OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY COMPOSITION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA OPHTHALMIC VISCOSURGICAL DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)